Marker Therapeutics Inc.

12/08/2024 | Press release | Distributed by Public on 12/08/2024 13:30

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT 601 in CAR Relapsed Patients with Non Hodgkin’s Lymphoma

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.